1
|
Günther G, Guglielmetti L, Kherabi Y, Duarte R, Lange C, Adamides T, Akkerman O, Andersen AB, Bakos Á, Bjarnason A, Bruchfeld J, Chesov D, Codecasa LR, Cirillo D, Danilovits M, Davidavičienė E, Duarte R, De Souza Galvão ML, Garnier S, Gjocaj M, Günther G, Ibraim E, Kappnik M, Khachatryan N, Klimuk D, Kuksa L, Jachym MF, Josefsdottir K, Kaluzhenina A, Lange C, Mack U, Makek MJ, Manika K, Mclaughlin AM, Mema D, Mengshoel AT, Muylle I, Nanovic Z, Özkara Ş, Perl S, Pesut D, Pierdou D, Ryskulov G, Skowroński M, Solovic I, Sukholytka M, Svetina P, Terleeva Y, Tiberi S, Togonidze T, Torri S, Turaev L, Usmanova R, Wirtz G, Vasankari T, Zhdanova E. Availability of drugs and resistance testing for BPaLM regimen for rifampicin-resistant tuberculosis in Europe. Clin Microbiol Infect 2024:S1198-743X(24)00121-6. [PMID: 38490355 DOI: 10.1016/j.cmi.2024.03.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/15/2024] [Revised: 02/13/2024] [Accepted: 03/05/2024] [Indexed: 03/17/2024]
Abstract
OBJECTIVES Multidrug-resistant/Rifampicin-resistant tuberculosis (TB) is a major obstacle to successful TB control. The recommendation by the World Health Organization to use bedaquiline, pretomanid, linezolid and moxifloxacin (BPaL(M)) for 6 months, based on results of three trials with high efficacy and low toxicity, has revolutionized treatment options. METHODS In this study, representatives of the Tuberculosis Network European Trialsgroup (TBnet) in 44/54 countries of the WHO Europe region document the availability of the medicines and drug susceptibility testing (DST) of the BPaL(M) regimen through a structured questionnaire between September to November 2023. RESULTS 24/44 (54.5%), 42/44 (95.5%), 43/44 (97.7%), and 43/44 (97.7%) had access to pretomanid, bedaquiline, linezolid, and moxifloxacin, respectively. Overall, 23/44 (52.3%) had access to all the drugs composing the BPaL(M) regimen. 7/44 (15.9%), 28/44 (63.6%), 34/44 (77.3%) and 36/44 (81.8%) had access to DST for pretomanid, bedaquiline, linezolid and moxifloxacin, respectively. DST was available for all medicines composing the BPaL(M) regimen in 6/44 (13.6%) countries. CONCLUSION Only in about half of the countries participating in the survey clinicians have access to all the BPaL(M) regimen drugs. In less than a fifth of countries, a complete DST is possible. Rapid scale up of DST capacity to prevent unnoticed spread of drug resistance and equal access to new regimens are urgently needed in Europe.
Collapse
Affiliation(s)
- Gunar Günther
- Department of Pulmonary Medicine and Allergology, Inselspital, Bern University Hospital, University of Bern, Switzerland; Department of Medical Sciences, School of Medicine, University of Namibia, Windhoek, Namibia
| | - Lorenzo Guglielmetti
- Sorbonne Université, INSERM, U1135, Centre d'Immunologie et des Maladies Infectieuses, Cimi-Paris, Paris, France; Assistance Publique Hopitaux de Paris, Groupe Hospitalier Universitaire Sorbonne Université, Hopital Pitié-Salpetrière, Centre National de Référence des Mycobactéries etde la Résistance des Mycobactéries aux Antituberculeux, Paris, France
| | - Yousra Kherabi
- Infectious and Tropical Diseases Department, Bichat-Claude Bernard Hospital, Assistance Publique-Hôpitaux de Paris, Université Paris Cité, Paris, France; Université Paris Cité, Inserm, IAME, Paris, France
| | - Raquel Duarte
- Unidade de Investigação em Epidemiologia (EPI Unit), Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal; Departamento de Saúde Comunitária, Estudos de Populações, Instituto de Ciências Biomédicas Abel Salazar, ICBAS, Universidade do Porto, Portugal; Serviço de Pneumologia, Centro Hospitalar Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal; Unidade de Investigação Clínica, Administração Regional de Saúde do Norte, Porto, Portugal
| | - Christoph Lange
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany; German Center for Infection Research (DZIF), Partner Site Hamburg-Lübeck-Borstel-Riems, Borstel, Germany; Respiratory Medicine and International Health, University of Lübeck, Lübeck, Germany; Baylor College of Medicine and Texas Children Hospital, Global TB Program, Houston, TX, USA.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Vasiliu A, Köhler N, Altpeter E, Ægisdóttir TR, Amerali M, de Oñate WA, Bakos Á, D'Amato S, Cirillo DM, van Crevel R, Davidaviciene E, Demuth I, Domínguez J, Duarte R, Günther G, Guthmann JP, Hatzianastasiou S, Holm LH, Herrador Z, Hribar U, Huberty C, Ibraim E, Jackson S, Jensenius M, Josefsdottir KS, Koch A, Korzeniewska-Kosela M, Kuksa L, Kunst H, Lienhardt C, Mahler B, Makek MJ, Muylle I, Normark J, Pace-Asciak A, Petrović G, Pieridou D, Russo G, Rzhepishevska O, Salzer HJF, Marques MS, Schmid D, Solovic I, Sukholytka M, Svetina P, Tyufekchieva M, Vasankari T, Viiklepp P, Villand K, Wallenfels J, Wesolowski S, Mandalakas AM, Martinez L, Zenner D, Lange C. Tuberculosis incidence in foreign-born people residing in European countries in 2020. Euro Surveill 2023; 28:2300051. [PMID: 37855907 PMCID: PMC10588305 DOI: 10.2807/1560-7917.es.2023.28.42.2300051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/24/2023] [Accepted: 05/12/2023] [Indexed: 10/20/2023] Open
Abstract
BackgroundEuropean-specific policies for tuberculosis (TB) elimination require identification of key populations that benefit from TB screening.AimWe aimed to identify groups of foreign-born individuals residing in European countries that benefit most from targeted TB prevention screening.MethodsThe Tuberculosis Network European Trials group collected, by cross-sectional survey, numbers of foreign-born TB patients residing in European Union (EU) countries, Iceland, Norway, Switzerland and the United Kingdom (UK) in 2020 from the 10 highest ranked countries of origin in terms of TB cases in each country of residence. Tuberculosis incidence rates (IRs) in countries of residence were compared with countries of origin.ResultsData on 9,116 foreign-born TB patients in 30 countries of residence were collected. Main countries of origin were Eritrea, India, Pakistan, Morocco, Romania and Somalia. Tuberculosis IRs were highest in patients of Eritrean and Somali origin in Greece and Malta (both > 1,000/100,000) and lowest among Ukrainian patients in Poland (3.6/100,000). They were mainly lower in countries of residence than countries of origin. However, IRs among Eritreans and Somalis in Greece and Malta were five times higher than in Eritrea and Somalia. Similarly, IRs among Eritreans in Germany, the Netherlands and the UK were four times higher than in Eritrea.ConclusionsCountry of origin TB IR is an insufficient indicator when targeting foreign-born populations for active case finding or TB prevention policies in the countries covered here. Elimination strategies should be informed by regularly collected country-specific data to address rapidly changing epidemiology and associated risks.
Collapse
Affiliation(s)
- Anca Vasiliu
- Baylor College of Medicine, Department of Pediatrics, Global and Immigrant Health, Global Tuberculosis Program, Houston, Texas, United States
| | - Niklas Köhler
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- German Center for Infection Research (DZIF), TTU-TB, Borstel, Germany
- Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany
| | - Ekkehardt Altpeter
- Swiss Federal Office of Public Health, Division of Communicable Diseases, Bern, Switzerland
| | - Tinna Rán Ægisdóttir
- The National University Hospital of Iceland, Pharmaceutical Services, Reykjavik, Iceland
| | - Marina Amerali
- Tuberculosis Control Office, Department of Respiratory Infections, Directorate for Epidemiological Surveillance & Intervention, National Public Health Organization (NPHO), Athens, Greece
| | - Wouter Arrazola de Oñate
- Belgian Lung and Tuberculosis Association, Brussels, Belgium
- Flemish Association of Respiratory Health and TB Control, Leuven, Belgium
| | - Ágnes Bakos
- Koranyi National Institute for Pulmonology, Budapest, Hungary
| | - Stefania D'Amato
- Prevention of Communicable Diseases and International Prophylaxis, General Direction of Health Prevention, Ministry of Health of Italy, Rome, Italy
| | - Daniela Maria Cirillo
- Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Reinout van Crevel
- Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, the Netherlands
- Centre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom
| | - Edita Davidaviciene
- Vilnius University hospital Santaros Klinikos, Department of Tuberculosis State information system, Vilnius, Lithuania
| | | | - Jose Domínguez
- Institut d'Investigació Germans Trias i Pujol; Universitat Autònoma de Barcelona; CIBER Enfermedades Respiratorias; INNOVA4TB consortium Badalona, Barcelona, Spain
| | - Raquel Duarte
- ICBAS - Instituto de Ciências Biomédicas Abel Salazar, Universidade do Porto
- ISPUP - Instituto de Saúde Pública da Universidade do Porto, Porto, Portugal
- Centro Hospitalar de Vila Nova de Gaia/Espinho, Porto, Portugal
| | - Gunar Günther
- Department of Pulmonary Medicine and Allergology, Inselspital, Bern University Hospital, University of Bern, Switzerland
- Department of Medical Sciences, School of Medicine, University of Namibia, Windhoek, Namibia
| | - Jean-Paul Guthmann
- Division of Infectious Diseases, Santé publique France, Saint-Maurice, France
| | - Sophia Hatzianastasiou
- Tuberculosis Control Office, Department of Respiratory Infections, Directorate for Epidemiological Surveillance & Intervention, National Public Health Organization (NPHO), Athens, Greece
| | - Louise Hedevang Holm
- Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
| | - Zaida Herrador
- Centro Nacional de Epidemiología, Instituto de Salud Carlos III, Madrid, Spain
| | - Urška Hribar
- Tuberculosis Register of the Republic of Slovenia, University Clinic Golnik, Golnik, Slovenia
| | | | - Elmira Ibraim
- Marius Nasta Institute of Pulmonology, Bucharest, Romania
| | - Sarah Jackson
- Infectious Diseases; Health Service Executive Health Protection Surveillance Centre, Dublin, Ireland
| | - Mogens Jensenius
- Department of Infectious Diseases, Oslo University Hospital, Ullevaal, Norway
| | | | - Anders Koch
- Department of Infectious Disease Epidemiology and Prevention, Statens Serum Institut, Copenhagen, Denmark
- Department of Infectious Diseases, Rigshospitalet University Hospital, Copenhagen, Denmark
| | - Maria Korzeniewska-Kosela
- Department of Tuberculosis Epidemiology and Surveillance, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
| | - Liga Kuksa
- Riga East University Hospital, TB and Lung Disease Clinic, Riga, Latvia
| | - Heinke Kunst
- Blizard Institute, The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
| | - Christian Lienhardt
- Unité Unité Mixte Internationale 233 IRD - U1175 INSERM - Université de Montpellier, Institut de Recherche pour le Développement (IRD), Montpellier, France
- Epidemiology and Population Health, Department of Infectious Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom
| | - Beatrice Mahler
- Marius Nasta Institute of Pulmonology, Bucharest, Romania
- Department Cardio-thoracic, Pneumophtisiology II, University of Medicine and Pharmacy "Carol Davila" Bucharest, Romania
| | - Mateja Janković Makek
- University of Zagreb, School of Medicine Zagreb, Croatia
- University Hospital Centre Zagreb, Department for Lung diseases, Zagreb, Croatia
| | - Inge Muylle
- Division of Pneumology, Onze-Lieve-Vrouw Ziekenhuis (OLV) Aalst, Aalst, Belgium
| | - Johan Normark
- Department of Clinical Microbiology, Umeå University, Sweden
- Wallenberg Centre for Molecular Medicine, Umeå University, Sweden
| | - Analita Pace-Asciak
- Infectious Disease Prevention and Control Unit, Health Promotion and Disease Prevention Directorate, Superintendence of Public Health, Ministry for Health of Malta, La Valetta, Malta
| | - Goranka Petrović
- Respiratory Diseases and Travel Medicine Department with Vaccination Unit, Infectious Diseases Epidemiology ServiceDepartment, Croatian Institute of Public Health, Zagreb, Croatia
| | - Despo Pieridou
- Cyprus National Reference Laboratory for Mycobacteria, Microbiology Department, Nicosia General Hospital, Nicosia, Cyprus
| | - Giulia Russo
- Emerging Bacterial Pathogens Unit, IRCCS San Raffaele Scientific Institute, Milan, Italy
| | - Olena Rzhepishevska
- Department of Chemistry, Department of Clinical Microbiology, Umeå University, Sweden
| | - Helmut J F Salzer
- Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine 4- Pneumology, Kepler University Hospital, Linz, Austria
- Faculty of Medicine, Johannes-Kepler-University, Linz, Austria and Ignaz Semmelweis Institut, Interuniversity Institute for Infection Resarch, Vienna, Austria
| | | | - Daniela Schmid
- Unit for Infectious Diseases Diagnostics and Infectious Diseases Epidemiology, Centre for Pathophysiology, Infectious Diseases and Immunology, Medical University of Vienna, Vienna, Austria
| | - Ivan Solovic
- National Institute for TB, Lung Diseases and Thoracic Surgery, Vysne Hagy, Slovakia
- Catholic University Ruzomberok, Ruzomberok, Slovakia
| | - Mariya Sukholytka
- First Faculty of Medicine and Faculty Thomayer Hospital Prague, Czechia
| | - Petra Svetina
- National TB Program and Tuberculosis Registry of Republic of Slovenia, University Clinic of Respiratory and Allergic Diseases Golnik, Golnik, Slovenia
| | - Mariya Tyufekchieva
- Health Promotion and Prevention Unit, Directorate Public Health Protection and Health Control, Ministry of Health of Bulgaria, Sofia, Bulgaria
| | - Tuula Vasankari
- University of Turku, Division of Medicine, Department of Pulmonary Diseases and Clinical Allergology, Turku, Finland
- Finnish Lung Health Association (Filha ry), Helsinki, Finland
| | - Piret Viiklepp
- Estonian Tuberculosis Register, Dept. of Registries, National Institute for Health Development, Tallinn, Estonia
| | - Kersti Villand
- Estonian Tuberculosis Register, Dept. of Registries, National Institute for Health Development, Tallinn, Estonia
| | - Jiri Wallenfels
- National TB Surveillance Unit, University Hospital Bulovka, Prague, Czechia
| | - Stefan Wesolowski
- Department of Tuberculosis Epidemiology and Surveillance, National Tuberculosis and Lung Diseases Research Institute, Warsaw, Poland
| | - Anna-Maria Mandalakas
- Baylor College of Medicine, Department of Pediatrics, Global and Immigrant Health, Global Tuberculosis Program, Houston, Texas, United States
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
| | - Leonardo Martinez
- Boston University, School of Public Health, Department of Epidemiology, Boston, Massachusetts, United States
| | - Dominik Zenner
- Global Public Health Unit, Wolfson Institute of Population Health Barts
- The London School of Medicine and Dentistry, Queen Mary University of London, London, United Kingdom
| | - Christoph Lange
- Baylor College of Medicine, Department of Pediatrics, Global and Immigrant Health, Global Tuberculosis Program, Houston, Texas, United States
- Division of Clinical Infectious Diseases, Research Center Borstel, Borstel, Germany
- German Center for Infection Research (DZIF), TTU-TB, Borstel, Germany
- Respiratory Medicine & International Health, University of Lübeck, Lübeck, Germany
| |
Collapse
|
3
|
Institóris L, Kovács K, Sija É, Berkecz R, Körmöczi T, Németh I, Elek I, Bakos Á, Urbán I, Pap C, Kereszty É. Clinical symptoms and blood concentration of new psychoactive substances (NPS) in intoxicated and hospitalized patients in the Budapest region of Hungary (2018-19). Clin Toxicol (Phila) 2021; 60:18-24. [PMID: 34080493 DOI: 10.1080/15563650.2021.1928162] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
BACKGROUND New Psychoactive Substances (NPS) impose a new challenge on the legal and health care system, yet, there is little information available about how new substances spread based on hospitalization of intoxicated patients. The aims of this study were: (i) to investigate the frequency of NPS among suspected drug intoxicated patients, (ii) to study the connection between blood concentration and clinical symptoms, (iii) to determine their half-life with a time-series blood sampling protocol. METHODS During the observation period, 116 suspected drug intoxicated patients were sampled. The samples were analyzed for alcohol, 20 classical illicit and licit drugs, and for 78 NPS. Clinical symptoms were registered on-site (by the Emergency Medical Services) and (also) at hospital admittance. RESULTS NPS were detected in 51 patients of which cathinones were found in 4, the synthetic cannabinoids (SCs) 5 F-MDMB-PINACA and 5 F-MDMB-PICA in 23-23, and CUMYL-CH-MEGACLONE in 2 cases. Poison severity scores (PSS) showed mild to moderate intoxications overall. Connection between blood concentration and severity of clinical symptoms were inconclusive. The calculated half-life of 5 F-MDMB-PINACA and 5 F-MDMB-PICA was 2.50 and 2.68 h, respectively. CONCLUSION The ratio of SCs among the selected intoxicated patients was higher than expected from seizure data which could be the consequence of targeted patient selection. The clinical symptoms and the severity of intoxication cannot be characterized simply by NPS blood levels. The short half-life of SCs can explain the relatively rapid consolidation of intoxication symptoms.HighlightsIn the Budapest region, the majority of hospitalized NPS intoxications was caused by the synthetic cannabinoids 5F-MDMB-PINACA and 5F-MDMB-PICA in 2018-19.No correlation between blood concentration and symptoms severity could be established.The clinical symptoms of synthetic cannabinoid users improved quickly and no ICU treatment was necessary.The half-life of 5F-MDMB-PINACA and 5F-MDMB-PICA was proved to be 2.50 hours and 2.68 hours, respectively.
Collapse
Affiliation(s)
- László Institóris
- Department of Forensic Medicine, University of Szeged, Szeged, Hungary
| | - Katalin Kovács
- Department of Forensic Medicine, University of Szeged, Szeged, Hungary
| | - Éva Sija
- Department of Forensic Medicine, University of Szeged, Szeged, Hungary
| | - Róbert Berkecz
- Institute of Pharmaceutical Analysis, University of Szeged, Szeged, Hungary.,Department of Medical Chemistry, University of Szeged, Szeged, Hungary
| | - Tímea Körmöczi
- Institute of Pharmaceutical Analysis, University of Szeged, Szeged, Hungary.,Department of Medical Chemistry, University of Szeged, Szeged, Hungary
| | - István Németh
- Biotech Statistics and Programming, Parexel International, Budapest, Hungary
| | - István Elek
- Department of Emergency and Clinical Toxicology (DECT), Péterfy Hospital-Clinic and Manninger Jenő Institute of Traumatology, Budapest, Hungary
| | - Ágnes Bakos
- Department of Emergency and Clinical Toxicology (DECT), Péterfy Hospital-Clinic and Manninger Jenő Institute of Traumatology, Budapest, Hungary
| | - Ildikó Urbán
- Department of Emergency and Clinical Toxicology (DECT), Péterfy Hospital-Clinic and Manninger Jenő Institute of Traumatology, Budapest, Hungary
| | - Csaba Pap
- Department of Emergency and Clinical Toxicology (DECT), Péterfy Hospital-Clinic and Manninger Jenő Institute of Traumatology, Budapest, Hungary
| | - Éva Kereszty
- Department of Forensic Medicine, University of Szeged, Szeged, Hungary
| |
Collapse
|
4
|
Bakos Á, Bátyi A. Methemoglobinemia caused by volatile nitrites derivates (‘poppers’). Orv Hetil 2021; 162:306-313. [PMID: 33611266 DOI: 10.1556/650.2021.32030] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2020] [Accepted: 09/05/2020] [Indexed: 11/19/2022]
Abstract
Összefoglaló. A methaemoglobinaemia az oxigén szállítására képtelen methemoglobin szintjének kóros emelkedését jelenti a vérben, ami jelentős szöveti oxigénhiányt okozhat, súlyos, akár életveszélyes tünetekhez vezethet. Methaemoglobinaemiát számos, oxidáló hatású exogén anyag idézhet elő, ezek közé tartoznak a partidrogként használt alkil-nitritek, az ún. "popperek" is. A "poppereket" korábban "alacsony rizikójú" drogként tartották számon, azonban számos esetet közöltek, amikor súlyos, időnként fatális kimenetelű methaemoglobinaemiát okoztak. A folyadékok gőzének belélegzése euforizáló, szexuálisvágy-fokozó és simaizom-lazító hatású, ezért a "popperek" igen népszerűek a homo- és biszexuális férfiak körében, de fiatal felnőttek és tinédzserek is használják. A folyadékok szájon át való fogyasztása különösen veszélyes. A szerzők két esetet ismertetnek, amelyekben a "popperek" használatát követően methaemoglobinaemia alakult ki. Mindkét betegnél, a jó általános állapot mellett, centrális és perifériás cyanosis tüneteit észlelték. Az alkalmazás módja (inhaláció/lenyelés), a methaemoglobinaemia súlyossága (16,4% és 57%) és a terápia eltérő volt a két betegnél. Az első beteg oxigén adása és tüneti kezelés mellett gyógyult, a másodiknál antidotum (metilénkék) adására is szükség volt. Mindketten panaszmentesen távoztak a kórházból. A szerzők célja az volt, hogy felhívják a figyelmet az illékony alkil-nitrit-származékok által okozott methaemoglobinaemiára, annak felismerésére, kezelésére, és bemutassák azok kevésbé ismert szövődményeit is. Orv Hetil. 2021; 162(8): 306-313. Summary. Methemoglobinemia means the abnormally elevated level of methemoglobin in the blood, which is incapable of oxygen transport, accordingly it can cause significant tissue hypoxia, leading to severe or even life-threatening clinical symptoms. Several exogen oxidative agents can induce methemoglobinemia, including alkyl-nitrites which are also used as party drugs, the so-called 'poppers'. The 'poppers' were previously considered 'low-risk' drugs, however, several cases have been published when they caused severe, sometimes fatal methemoglobinemia. Inhaling vapours from liquids has euphoric, smooth-muscle relaxing and aphrodisiac effects, therefore 'poppers' are extremely popular among gay and bisexual men but also used by young adults and teenagers. Oral consumption of the fluids is particularly dangerous. The authors present two cases when methemoglobinemia developed after 'poppers' usage. Both patients were in good general condition and symptoms of central and peripheral cyanosis were detected. The method of application (inhalation/ ingestion), the severity of methemoglobinemia (16,4% and 57%) and the treatment were different in the two patients. The first patient recovered with inhalation of oxygen and symptomatic treatment; the second patient required administration of antidote (methylene blue). Both patients left the hospital without complaints. The authors' aim was to attract attention to methemoglobinemia caused by volatile alkyl-nitrites, its recognition, treatment and to present their lesser-known complications. Orv Hetil. 2021; 12(8): 306-313.
Collapse
Affiliation(s)
- Ágnes Bakos
- 1 Péterfy Kórház-Rendelőintézet és Manninger Jenő Országos Traumatológiai Intézet, Sürgősségi Belgyógyászat és Klinikai Toxikológiai Osztály, Budapest, Alsóerdősor u. 7., 1074
| | - Anna Bátyi
- 1 Péterfy Kórház-Rendelőintézet és Manninger Jenő Országos Traumatológiai Intézet, Sürgősségi Belgyógyászat és Klinikai Toxikológiai Osztály, Budapest, Alsóerdősor u. 7., 1074
| |
Collapse
|
5
|
Jagielski T, Aleksa A, Bachiyska E, Bakos Á, Crudu V, Dziadek J, Homolka J, Homorodean D, Jansone I, Katalinic-Jankovic V, Krenke R, Kuzmic U, Mokrousov I, Nikolayevskyy V, Nikolenka A, Osmani GM, Papaventsis D, Pole I, Porvazník I, Savic B, Shubladze N, Solovic I, Szabó N, Tafaj S, Ustamujic A, van Ingen J, Vasiliauskiene E, Yablonsky PK, Zemanova I, Zhuravlev V, Žolnir-Dovc M. FATE: the new partnership to Fight Against TB in Central and Eastern Europe. The Lancet Infectious Diseases 2017; 17:363. [DOI: 10.1016/s1473-3099(17)30120-2] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/13/2017] [Revised: 02/22/2017] [Accepted: 02/24/2017] [Indexed: 11/28/2022]
|
6
|
Rikker C, Bakos Á, Balla J, Fazakas J, Bobek I, Kondor B, Tamási P, Rácz E, Tóvárosi S, Rosivall L. FP544PROMETHEUS LIVER SUPPORT THERAPY IN HUNGARY. Nephrol Dial Transplant 2015. [DOI: 10.1093/ndt/gfv179.73] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
7
|
Mezei M, Áy É, Koroknai A, Tóth R, Balázs A, Bakos Á, Győri Z, Bánáti F, Marschalkó M, Kárpáti S, Minárovits J. Molecular epidemiological analysis of env and pol sequences in newly diagnosed HIV type 1-infected, untreated patients in Hungary. AIDS Res Hum Retroviruses 2011; 27:1243-7. [PMID: 21453184 DOI: 10.1089/aid.2011.0077] [Citation(s) in RCA: 12] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
The aim of our study was to monitor the diversity of HIV-1 strains circulating in Hungary and investigate the prevalence of resistance-associated mutations to reverse transcriptase (RT) and protease (PR) inhibitors in newly diagnosed, drug-naive patients. A total of 30 HIV-1-infected patients without prior antiretroviral treatment diagnosed during the period 2008-2010 were included into this study. Viral subtypes and the presence of RT, PR resistance-associated mutations were established by sequencing. Classification of HIV-1 strains showed that 29 (96.6%) patients were infected with subtype B viruses and one patient (3.3%) with subtype A virus. The prevalence of HIV-1 strains with transmitted drug resistance mutations in newly diagnosed individuals was 16.6% (5/30). This study showed that HIV-1 subtype B is still highly predominant in Hungary and documented a relatively high transmission rate of drug resistance in our country.
Collapse
Affiliation(s)
- Mária Mezei
- National Center for Epidemiology, Microbiological Research Group, Budapest, Hungary
| | - Éva Áy
- National Center for Epidemiology, Microbiological Research Group, Budapest, Hungary
| | - Anita Koroknai
- National Center for Epidemiology, Microbiological Research Group, Budapest, Hungary
| | - Renáta Tóth
- Department of Microbiology, Eötvös Loránd University, Budapest, Hungary
| | - Andrea Balázs
- Department of Microbiology, Eötvös Loránd University, Budapest, Hungary
| | - Ágnes Bakos
- National Center for Epidemiology, Microbiological Research Group, Budapest, Hungary
| | - Zoltán Győri
- National Center for Epidemiology, Microbiological Research Group, Budapest, Hungary
| | - Ferenc Bánáti
- National Center for Epidemiology, Microbiological Research Group, Budapest, Hungary
| | - Márta Marschalkó
- Department of Dermatology,Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
| | - Sarolta Kárpáti
- Department of Dermatology,Venereology and Dermatooncology, Semmelweis University, Budapest, Hungary
| | - János Minárovits
- National Center for Epidemiology, Microbiological Research Group, Budapest, Hungary
| |
Collapse
|
8
|
Bakos Á, Rikker C, Tóvárosi S, Kárteszi †M. The therapeutical efficiency of the newest extracorporal elimination procedure (Prometheus® treatment) in acute liver failure caused by intoxication. Orv Hetil 2007; 148:1981-8. [DOI: 10.1556/oh.2007.28171] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Az akut májelégtelenség mortalitása az intenzív terápia ellenére májtranszplantáció nélkül 60–90%. Az átültethető szervek korlátozott száma miatt azonban a betegek jelentős része a várólistán exitál. A mortalitás csökkentése érdekében számos próbálkozás történt a májelégtelenségben felhalmozódó albuminhoz kötött és vízoldékony méreganyagok eltávolítására, elősegítve ezzel a máj spontán regenerációját, illetve a beteg életben tartását a májtranszplantációig. A Prometheus®-kezelés egy viszonylag új technika, a frakcionált plazmaszeparáció és -adszorpció (FPSA) és egy high-flux dialízis kombinációja. Az eljárás során a beteg saját, szeparált, albuminban gazdag plazmája speciális adszorbereken halad keresztül, lehetővé téve az albuminhoz kötött toxinok eliminációját, miközben a vízoldékony toxinok eltávolítása hemodialízissel történik.
Célkitűzés:
A szerzők szándéka az volt, hogy a Prometheus®-kezelés hatékonyságát igazolják mérgezés okozta akut májelégtelenségben.
Betegek és módszer:
A Prometheus®-kezelést három, konzervatív kezeléssel nem uralható akut májelégtelenségben szenvedő, súlyos, paracetamol-, káliumpermanganát- és Amanita phalloides-mérgezett beteg esetében alkalmazták.
Eredmények:
A három nőbetegnél 10 kezelés történt. Súlyos szövődményt nem észleltek. A kezelések során az albuminhoz kötött (indirekt bilirubin
p
= 0,048; epesav
p
= 0,001) és a vízoldékony (direkt bilirubin
p
= 0,002; kreatinin
p
= 0,007) toxinok szignifikáns csökkenését tapasztalták. Az ammónia, a karbamid, a fibrinogén és az antitrombin III szint szignifikánsan nem változott. Mindhárom beteg májtranszplantáció nélkül meggyógyult.
Következtetés:
A Prometheus®-kezelés hatékonyan távolítja el az akut májelégtelenségben akkumulálódó toxinokat. Biztonságos eljárás. Konzervatív terápiával nem uralható esetekben lehetővé teszi a beteg életben tartását a máj spontán regenerációjáig vagy a májtranszplantációig.
Collapse
Affiliation(s)
- Ágnes Bakos
- 1 Péterfy Sándor utcai Kórház és Rendelőintézet Sürgősségi Belgyógyászati és Klinikai Toxikológiai Osztály Budapest Alsóerdősor u. 7. 1074
| | - Csaba Rikker
- 2 Péterfy Sándor utcai Kórház és Rendelőintézet Fresenius Medical Care Dialízis Központ Budapest
| | | | - †Mihály Kárteszi
- 1 Péterfy Sándor utcai Kórház és Rendelőintézet Sürgősségi Belgyógyászati és Klinikai Toxikológiai Osztály Budapest Alsóerdősor u. 7. 1074
| |
Collapse
|
9
|
Bakos Á, Borsics T, Toldi O, Babos K, Lados M. Evidence for somatic embryogenesis during plant regeneration from seedling-derived callus of dodder (Cuscuta trifolii Bab. et Gibs). Plant Cell Rep 2000; 19:525-528. [PMID: 30754894 DOI: 10.1007/s002990050767] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
In this paper comparative histological studies of embryo-like structures originating from callus cultures, and zygotic embryos originating from sexual seeds of Cuscuta trifolii are reported. The embryos of somatic cell and zygote origin showed similar morphological and anatomical features, such as a complete lack of cotyledon development and the differentiation of a developmentally unique root primordium specialised for water storage. Based on these findings, the regeneration of C. trifolii from callus cultures is shown to proceed along the pathway of somatic embryogenesis.
Collapse
Affiliation(s)
- Á Bakos
- National Center for Epidemiology, H-1529 Budapest, Hungary e-mail: Fax: +36-1-3945409, , , , , , HU
| | - T Borsics
- Agricultural Biotechnology Center, H-2101 Gödöllő, P.O. Box 411, Hungary e-mail: Fax: +36-28-430416, , , , , , HU
| | - O Toldi
- Agricultural Biotechnology Center, H-2101 Gödöllő, P.O. Box 411, Hungary e-mail: Fax: +36-28-430416, , , , , , HU
| | - K Babos
- ELTE Department of Plant Anatomy, H-1088 Budapest, Puskin u. 11-13, Hungary, , , , , , HU
| | - M Lados
- Agricultural Biotechnology Center, H-2101 Gödöllő, P.O. Box 411, Hungary e-mail: Fax: +36-28-430416, , , , , , HU
| |
Collapse
|